Core Insights - Praxis Precision Medicines has successfully completed discussions with the FDA, confirming the path to file a New Drug Application (NDA) for relutrigine in early 2026 [1][2] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, particularly those related to neuronal excitation-inhibition imbalance [4] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [4] Product Development - Relutrigine is a first-in-class small molecule aimed at treating developmental and epileptic encephalopathies (DEEs) by inhibiting persistent sodium current, which is a key factor in seizure symptoms [3] - In vivo studies have shown that relutrigine can achieve dose-dependent inhibition of seizures, with complete control observed in certain mouse models [3] - The EMBOLD study demonstrated a well-tolerated safety profile for relutrigine, with significant improvements in motor seizures among heavily pre-treated patients [3] Regulatory Designations - Relutrigine has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation from the FDA for SCN2A-DEE, SCN8A-DEE, and Dravet syndrome, as well as Breakthrough Therapy Designation (BTD) from the European Medicines Agency [3]

Core Insights - Praxis Precision Medicines announced positive results from the EMBOLD study for relutrigine, leading to an early stop for efficacy as recommended by the Data Monitoring Committee [1][2] - The results will be presented at the American Epilepsy Society Annual Meeting on December 6, 2025, and the FDA has confirmed a meeting to discuss the data and NDA path [1][3] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly those related to neuronal excitation-inhibition imbalance [5] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [5] Product Information - Relutrigine is a first-in-class small molecule targeting developmental and epileptic encephalopathies (DEEs) by inhibiting persistent sodium current, which is a key driver of seizure symptoms [4] - In vivo studies have shown that relutrigine can achieve dose-dependent inhibition of seizures, with some patients experiencing maintained seizure freedom [4] - The drug has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, as well as Breakthrough Therapy Designation from the European Medicines Agency for SCN2A-DEE and SCN8A-DEE [4]

Core Insights - Praxis Precision Medicines has reached alignment with the FDA regarding the relutrigine program for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) following a comprehensive Type B meeting [1][2] - The company plans to conduct an interim analysis of the EMBOLD cohort 2 pivotal trial in Q4 2025, which, if positive, could support a New Drug Application (NDA) submission in early 2026 [1][2] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly those related to neuronal excitation-inhibition imbalance [6] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms [6] Product Development - Relutrigine (PRAX-562) is a first-in-class small molecule being developed for the treatment of DEEs, showing promise in preclinical studies and early clinical trials [5] - The EMBOLD study involves a randomized trial design to evaluate the efficacy of relutrigine in reducing seizure frequency among patients [3][4] - The interim analysis will assess approximately 70% of patients enrolled in the study, with a focus on achieving statistically significant results [4] Market Context - SCN2A and SCN8A-DEEs are ultra-rare, life-threatening pediatric epilepsies with no FDA-approved therapies currently available, affecting around 5,000 patients in the US [2] - The only existing treatment option is off-label polytherapy with antiseizure medications (ASMs), which is largely ineffective and carries significant risks [2]

Core Insights - The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for relutrigine, a sodium channel functional state modulator, aimed at treating pediatric patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) [1][2] - The EMBOLD cohort 2 pivotal trial is expected to deliver topline results in the first half of 2026, with a New Drug Application (NDA) filing to follow [1][3] - Praxis has initiated the EMERALD study to evaluate relutrigine in a broader DEE patient population [1][3] Clinical Trial Results - The EMBOLD cohort 1 study included a severely affected DEE population, with patients averaging three failed treatments prior to enrollment [2] - Results from the open-label extension of the study showed approximately 90% reduction in seizures and an average of 67 days without seizures compared to 3 days in the baseline period [2][4] - During the double-blind period, a placebo-adjusted monthly motor seizure reduction of 46% was observed, with over 30% of patients achieving seizure freedom while on relutrigine [2][4] Drug Mechanism and Designation - Relutrigine is a first-in-class small molecule that preferentially inhibits persistent sodium current, a key driver of seizure symptoms in severe DEEs [4] - The drug has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation from the FDA for SCN2A-DEE and SCN8A-DEE, in addition to the BTD [4][5] Company Overview - Praxis Precision Medicines is focused on developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, utilizing genetic insights [6] - The company has a diversified CNS portfolio, including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates [6]

Company Overview - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance [3] - The company utilizes genetic insights to create therapies for both rare and more prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - Praxis has a diversified CNS portfolio that includes multiple programs across epilepsy and movement disorders, featuring four clinical-stage product candidates [3] Upcoming Event - Praxis will host a virtual investor event on May 2, 2025, from 10:00 a.m. to 11:30 a.m. EDT, focusing on its clinical programs in developmental and epileptic encephalopathies (DEEs) [1][2] - The event will be led by the Praxis management team, and a replay will be available for 90 days on the company's website [2] Clinical Studies - The company is conducting several studies, including: - The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs [4] - The EMERALD study evaluating relutrigine for broader DEEs [4] - The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE [4]